In summary, our findings support the prognostic and therapeutic importance of CHRNA7 in nicotine-induced cancer-initiating properties, by showing that a combination of dextromethorphan and metformin may serve as either a preventive (e.g., secondary prevention) or therapeutic strategy against nicotine-relevant cancers. Here, CHRNA7 is linked to cancer.